• News
  • SAN DIEGO
  • BioTech

Gilead Climbs on Study Results of Hepatitis C Combo Treatment

Nov. 12 (Bloomberg) -- Gilead Sciences Inc. rose after a combination of its experimental hepatitis C therapies cleared the virus in 100 percent of patients in a trial.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments
Subscribe Today!